Today Bioceltix debuted on the NewConnect market! The debut rate increased by over 70%. Bioceltix develop innovative biopharmaceuticals based on stem cells for companion animals, with with focus on dogs and horses, based on stem cells.
The company’s business model assumes the future sale to industry partners of rights to the developed medicinal products, as well as production based on its own production plant operating in the pharmaceutical quality standard.
The company’s debut you can viewed here.